149 related articles for article (PubMed ID: 8809640)
1. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation.
Messori A; Trippoli S; Tendi E
J Clin Pharm Ther; 1996 Apr; 21(2):57-63. PubMed ID: 8809640
[TBL] [Abstract][Full Text] [Related]
2. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
4. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
[TBL] [Abstract][Full Text] [Related]
5. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
7. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
8. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.
Frampton JE; Faulds D
Pharmacoeconomics; 1996 Jan; 9(1):76-96. PubMed ID: 10161371
[TBL] [Abstract][Full Text] [Related]
9. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
Cosler LE; Eldar-Lissai A; Culakova E; Kuderer NM; Dale D; Crawford J; Lyman GH
Pharmacoeconomics; 2007; 25(4):343-51. PubMed ID: 17402806
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
Calhoun EA; Schumock GT; McKoy JM; Pickard S; Fitzner KA; Heckinger EA; Powell EF; McCaffrey KR; Bennett CL
Pharmacoeconomics; 2005; 23(8):767-75. PubMed ID: 16097839
[TBL] [Abstract][Full Text] [Related]
12. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.
Lyman GH
Eur J Cancer; 2000 Apr; 36 Suppl 1():S15-21. PubMed ID: 10785605
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.
Esser M; Brunner H
Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898
[TBL] [Abstract][Full Text] [Related]
16. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
[TBL] [Abstract][Full Text] [Related]
17. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
18. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
19. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
20. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis.
Numnum TM; Kimball KJ; Rocconi RP; Kilgore LC; Straughn JM
Int J Gynecol Cancer; 2007; 17(5):1019-24. PubMed ID: 17386043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
